Posttransplant lymphoproliferative disease after pediatric solid organ transplantation

Clinical and Developmental Immunology

Volumn 2013, Issue , 2013, Pages

  Mynarek, Martin ^a   Schober, Tilmann ^b   Behrends, Uta ^c   Maecker Kolhoff, Britta ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CIDOFOVIR; CYCLOPHOSPHAMIDE; CYTOMEGALOVIRUS ANTIBODY; DNA VACCINE; DOXORUBICIN; EVEROLIMUS; GANCICLOVIR; PREDNISONE; RAPAMYCIN; RITUXIMAB; VALGANCICLOVIR; VINCRISTINE;

AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIPROLIFERATIVE ACTIVITY; B LYMPHOCYTE; BURKITT LYMPHOMA; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CLASSICAL HODGKIN LYMPHOMA; CYTOMEGALOVIRUS; DISEASE CLASSIFICATION; DISEASE COURSE; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GENE MUTATION; HEART GRAFT; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTESTINE GRAFT; KIDNEY GRAFT; LIVER GRAFT; LYMPHOCYTE PROLIFERATION; MONITORING; MULTIPLE CYCLE TREATMENT; ORGAN TRANSPLANTATION; OVERALL SURVIVAL; PATHOGENESIS; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SKULL IRRADIATION; SOLID ORGAN TRANSPLANTATION; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE; VIRUS LOAD; ADOLESCENT; CHILD; LYMPHOPROLIFERATIVE DISEASE; PRESCHOOL CHILD;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; ORGAN TRANSPLANTATION; PROGNOSIS; RISK FACTORS;

EID: 84885642655     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2013/814973     Document Type: Review

References (132)

1. Engels E. A., Pfeiffer R. M., Fraumeni J. F. Jr., Kasiske B. L., Israni A. K., Snyder J. J., Wolfe R. A., Goodrich N. P., Bayakly A. R., Clarke C. A., Copeland G., Finch J. L., Fleissner M. L., Goodman M. T., Kahn A., Koch L., Lynch C. F., Madeleine M. M., Pawlish K., Rao C., Williams M. A., Castenson D., Curry M., Parsons R., Fant G., Lin M., Spectrum of cancer risk among US solid organ transplant recipients. Journal of the American Medical Association 2011 306 17 1891 1901 2-s2.0-80355135138 10.1001/jama.2011.1592
2. Buell J. F., Gross T. G., Thomas M. J., Neff G., Muthiah C., Alloway R., Ryckman F. C., Tiao G. M., Woodle E. S., Malignancy in pediatric transplant recipients. Seminars in Pediatric Surgery 2006 15 3 179 187 2-s2.0-33745481498 10.1053/j.sempedsurg.2006.03.005 (Pubitemid 43963388)
3. Webber S. A., Naftel D. C., Fricker F. J., Olesnevich P., Blume E. D., Addonizio L., Kirklin J. K., Canter C. E., Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study. The Lancet 2006 367 9506 233 239 2-s2.0-30844432417 10.1016/S0140-6736(06)67933-6 (Pubitemid 43107668)
4. Parker A., Bowles K., Bradley J. A., Emery V., Featherstone C., Gupte G., Marcus R., Parameshwar J., Ramsay A., Newstead C., Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients-BCSH and BTS Guidelines. British Journal of Haematology 2010 149 5 675 692 2-s2.0-77952718329 10.1111/j.1365-2141.2010.08161.x
5. Schuster V., Kreth H. W., Epstein-Barr virus infection and associated diseases in children. I. Pathogenesis, epidemiology and clinical aspects. European Journal of Pediatrics 1992 151 10 718 725 2-s2.0-0026779366
6. Amon W., Farrell P. J., Reactivation of Epstein-Barr virus from latency. Reviews in Medical Virology 2005 15 3 149 156 2-s2.0-18744390485 10.1002/rmv.456 (Pubitemid 40675906)
7. Cohen J. I., Epstein-Barr virus infection. The New England Journal of Medicine 2000 343 7 481 492 2-s2.0-0034680005 10.1056/NEJM200008173430707 (Pubitemid 30646489)
8. Thorley-Lawson D. A., Gross A., Persistence of the epstein-barr virus and the origins of associated lymphomas. The New England Journal of Medicine 2004 350 13 1328 1337 2-s2.0-1642334164 10.1056/NEJMra032015 (Pubitemid 38375368)
9. Young L. S., Rickinson A. B., Epstein-Barr virus: 40 years on. Nature Reviews Cancer 2004 4 10 757 768 2-s2.0-4944266319 10.1038/nrc1452 (Pubitemid 39331148)
10. Schober T., Framke T., Kreipe H., Schulz T. F., Grohennig A., Hussein K., Baumann U., Pape L., Schubert S., Wingen A. M., Jack T., Koch A., Klein C., Maecker-Kolhoff B., Characteristics of early and late PTLD development in pediatric solid organ transplant recipients. Transplantation 2013 95 240 246
11. Laichalk L. L., Hochberg D., Babcock G. J., Freeman R. B., Thorley-Lawson D. A., The dispersal of mucosal memory B cells: evidence from persistent EBV infection. Immunity 2002 16 5 745 754 2-s2.0-0036286141 10.1016/S1074-7613(02) 00318-7 (Pubitemid 34626694)
12. Long H. M., Taylor G. S., Rickinson A. B., Immune defence against EBV and EBV-associated disease. Current Opinion in Immunology 2011 23 2 258 264 2-s2.0-79953068030 10.1016/j.coi.2010.12.014
13. Höcker B., Fickenscher H., Delecluse H.-J., Böhm S., Küsters U., Schnitzler P., Pohl M., John U., Kemper M. J., Fehrenbach H., Wigger M., Holder M., Schröder M., Billing H., Fichtner A., Feneberg R., Sander A., Köpf-Shakib S., Süsal C., Tönshoff B., Epidemiology and morbidity of epstein-barr virus infection in pediatric renal transplant recipients: a multicenter, prospective study. Clinical Infectious Diseases 2013 56 84 92
14. Rea D., Fourcade C., Leblond V., Rowe M., Joab I., Edelman L., Bitker-M. O., Gandjbakhch I., Suberbielle C., Farcet J.-P., Raphael M., Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation. Transplantation 1994 58 3 317 324 2-s2.0-0028068354 (Pubitemid 24252285)
15. Maecker B., Jack T., Zimmermann M., Abdul-Khaliq H., Burdelski M., Fuchs A., Hoyer P., Koepf S., Kraemer U., Laube G. F., Müller-Wiefel D. E., Netz H., Pohl M., Toenshoff B., Wagner H., Wallot M., Welte K., Melter M., Offner G., Klein C., CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. Journal of Clinical Oncology 2007 25 31 4902 4908 2-s2.0-36849072665 10.1200/JCO.2006.10.2392 (Pubitemid 350220420)
16. Chinnock R., Webber S. A., Dipchand A. I., A 16-year multi-institutional study of the role of age and EBV status on PTLD incidence among pediatric heart transplant recipients. American Journal of Transplantation 2012 12 3061 3068
17. Dharnidharka V. R., Lamb K. E., Gregg J. A., Meier-Kriesche H.-U., Associations between EBV serostatus and organ transplant type in PTLD risk: an analysis of the SRTR national registry data in the United States. American Journal of Transplantation 2012 12 4 976 983 2-s2.0-84859311382 10.1111/j.1600-6143.2011.03893.x
18. Funch D. P., Hnin H. K., Travasso J., Brady J., Kew C. E. II, Nalesnik M. A., Walker A. M., Posttransplant lymphoproliferative disorder among renal transplant patients in relation to the use of mycophenolate mofetil. Transplantation 2005 80 9 1174 1180 2-s2.0-28544450172 10.1097/01.tp.0000169035. 10572.c6 (Pubitemid 41746793)
19. Sampaio M. S., Cho Y. W., Shah T., Bunnapradist S., Hutchinson I. V., Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients. Transplantation 2012 93 1 73 81 2-s2.0-84655170254 10.1097/TP.0b013e31823ae7db
20. Opelz G., Daniel V., Naujokat C., Döhler B., Epidemiology of pretransplant ebv and cmv serostatus in relation to posttransplant non-hodgkin lymphoma. Transplantation 2009 88 8 962 967 2-s2.0-70350450387 10.1097/TP.0b013e3181b9692d
21. Dharnidharka V. R., Tejani A. H., Ho P., Harmon W. E., Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk. American Journal of Transplantation 2002 2 10 993 998 2-s2.0-0345269141 10.1034/j.1600-6143.2002.21019.x (Pubitemid 36330232)
22. Opelz G., Döhler B., Lymphomas after solid organ transplantation: a collaborative transplant study report. American Journal of Transplantation 2004 4 2 222 230 2-s2.0-1342304173 10.1046/j.1600-6143.2003.00325.x (Pubitemid 38248525)
23. Dharnidharka V. R., Kenneth Sullivan E., Stablein D. M., Tejani A. H., Harmon W. E., Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American pediatric renal transplant cooperative study (NAPRTCS). Transplantation 2001 71 8 1065 1068 2-s2.0-0035041317 (Pubitemid 32448820)
24. D'Alessandro A. M., Knechtle S. J., Chin L. T., Fernandez L. A., Yagci G., Leverson G., Kalayoglu M., Liver transplantation in pediatric patients: twenty years of experience at the University of Wisconsin. Pediatric Transplantation 2007 11 6 661 670 2-s2.0-34547483938 10.1111/j.1399-3046.2007. 00737.x (Pubitemid 47174393)
25. Jain A., Nalesnik M., Reyes J., Pokharna R., Mazariegos G., Green M., Eghtesad B., Marsh W., Cacciarelli T., Fontes P., Abu-Elmagd K., Sindhi R., Demetris J., Fung J., Russell P. S., Bartlett S. T., Najarian J. S., Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Annals of Surgery 2002 236 4 429 436 2-s2.0-0036786654 10.1097/00000658-200210000-00005
26. Pinho-Apezzato M. L., Tannuri U., Tannuri A. C. A., Mello E. S., Lima F., Gibelli N. E., Santos M. M., Ayoub A. A., Maksoud-Filho J. G., Velhote M. C., Silva M. M., Andrade W. C., Miyatani H. T., Multiple clinical presentations of lymphoproliferative disorders in pediatric liver transplant recipients: a single-center experience. Transplantation Proceedings 2010 42 5 1763 1768 2-s2.0-77953669080 10.1016/j.transproceed.2010.01.077
27. Cohen A. H., Sweet S. C., Mendeloff E., Mallory G. B. Jr., Huddleston C. B., Kraus M., Kelly M., Hayashi R., DeBaun M. R., High incidence of posttransplant lymphoproliferative disease in pediatric patients with cystinc fibrosis. American Journal of Respiratory and Critical Care Medicine 2000 161 4 I 1252 1255 2-s2.0-0034012157 (Pubitemid 30243838)
28. Elidemir O., Kancherla B. S., Schecter M. G., McKenzie E. D., Morales D. L., Heinle J. S., Mallory G. B., Post-transplant lymphoproliferative disease in pediatric lung transplant recipients: recent advances in monitoring. Pediatric Transplantation 2009 13 5 606 610 2-s2.0-67651183952 10.1111/j.1399-3046.2008. 01085.x
29. Quintini C., Kato T., Gaynor J. J., Ueno T., Selvaggi G., Gordon P., McLaughlin G., Tompson J., Ruiz P., Tzakis A., Analysis of risk factors for the development of posttransplant lymphoprolipherative disorder among 119 children who received primary intestinal transplants at a single center. Transplantation Proceedings 2006 38 6 1755 1758 2-s2.0-33746893007 10.1016/j.transproceed.2006. 05.039 (Pubitemid 44190042)
30. Opelz G., Döhler B., Pediatric kidney transplantation: analysis of donor age, HLA match, and posttransplant non-hodgkin lymphoma: a collaborative transplant study report. Transplantation 2010 90 3 292 297 2-s2.0-77955429321 10.1097/TP.0b013e3181e46a22
31. Glotz D., Chapman J. R., Dharnidharka V. R., Hanto D. W., Castro M. C., Hirsch H. H., Leblond V., Mehta A. K., Moulin B., Pagliuca A., Pascual J., Rickinson A. B., Russo F. P., Trappe R. U., Webster A. C., Zuckermann A. O., Gross T. G., The Seville expert workshop for progress in posttransplant lymphoproliferative disorders. Transplantation 2012 94 784 793
32. Kremers W. K., Devarbhavi H. C., Wiesner R. H., Krom R. A. F., Macon W. R., Habermann T. M., Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. American Journal of Transplantation 2006 6 5 I 1017 1024 2-s2.0-33745236062 10.1111/j.1600-6143. 2006.01294.x (Pubitemid 44356653)
33. Caillard S., Dharnidharka V., Agodoa L., Bohen E., Abbott K., Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005 80 9 1233 1243 2-s2.0-28544449370 10.1097/01.tp.0000179639.98338.39 (Pubitemid 41746802)
34. Opelz G., Naujokat C., Daniel V., Terness P., Döhler B., Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 2006 81 9 1227 1233 2-s2.0-33744457937 10.1097/01.tp.0000219817.18049.36 (Pubitemid 43804539)
35. Gajarski R. J., Blume E. D., Urschel S., Schechtman K., Zheng J., West L. J., Altamirano L., Miyamoto S., Naftel D. C., Kirklin J. K., Zamberlan M. C., Canter C. E., Infection and malignancy after pediatric heart transplantation: the role of induction therapy. Journal of Heart and Lung Transplantation 2011 30 3 299 308 2-s2.0-79551684833 10.1016/j.healun.2010.09.005
36. Manlhiot C., Pollock-BarZiv S. M., Holmes C., Weitzman S., Allen U., Clarizia N. A., Ngan B., McCrindle B. W., Dipchand A. I., Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients. Journal of Heart and Lung Transplantation 2010 29 6 648 657 2-s2.0-77952583508 10.1016/j.healun.2010.01.013
37. O'Neill J. O., Edwards L. B., Taylor D. O., Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the international society for heart and lung transplantation. Journal of Heart and Lung Transplantation 2006 25 10 1186 1191 2-s2.0-33749507195 10.1016/j.healun.2006.06.010 (Pubitemid 44528284)
38. Robson R., Cecka J. M., Opelz G., Budde M., Sacks S., Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. American Journal of Transplantation 2005 5 12 2954 2960 2-s2.0-33644821539 10.1111/j.1600-6143.2005.01125.x (Pubitemid 43923957)
39. El-Salem M., Raghunath P. N., Marzec M., Wlodarski P., Tsai D., Hsi E., Wasik M. A., Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders. Laboratory Investigation 2007 87 1 29 39 2-s2.0-33845775754 10.1038/labinvest.3700494 (Pubitemid 44973651)
40. Nelson B. P., Wolniak K. L., Evens A., Chenn A., Maddalozzo J., Proytcheva M., Early posttransplant lymphoproliferative disease: clinicopathologic features and correlation with mTOR signaling pathway activation. American Journal of Clinical Pathology 2012 138 568 578
41. Nee R., Hurst F. P., Dharnidharka V. R., Jindal R. M., Agodoa L. Y., Abbott K. C., Racial variation in the development of posttransplant lymphoproliferative disorders after renal transplantation. Transplantation 2011 92 2 190 195 2-s2.0-79960300318 10.1097/TP.0b013e3182200e8a
42. Swerdlow S. H., Campo E., Harris N. L., Jaffe E. S., Pileri S. A., Stein H., Thiele J., Vardiman J. W., WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008 4th
43. Hussein K., Maecker-Kolhoff B., Klein C., Kreipe H., Transplant- associated lymphoproliferation. Pathologe 2011 32 2 152 158 2-s2.0-79955723315 10.1007/s00292-010-1407-x
44. Starzl T. E., Nalesnik M. A., Porter K. A., Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. The Lancet 1984 1 8377 583 587 2-s2.0-0021349053 (Pubitemid 14156511)
45. Swinnen L. J., Leblanc M., Grogan T. M., Gordon L. I., Stiff P. J., Miller A. M., Kasamon Y., Miller T. P., Fisher R. I., Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation 2008 86 2 215 222 2-s2.0-49249097559 10.1097/TP.0b013e3181761659
46. Tsai D. E., Hardy C. L., Tomaszewski J. E., Kotloff R. M., Oltoff K. M., Somer B. G., Schuster S. J., Porter D. L., Montone K. T., Stadtmauer E. A., Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001 71 8 1076 1088 2-s2.0-0035025775 (Pubitemid 32448822)
47. Cleper R., Ben Shalom E., Landau D., Weissman I., Krause I., Konen O., Rahamimov R., Mor E., Bar-Nathan N., Frishberg Y., Davidovits M., Post-transplantation lymphoproliferative disorder in pediatric kidney-transplant recipients-a national study. Pediatr Transplant 2012 16 619 626
48. McDonald R. A., Smith J. M., Ho M., Lindblad R., Ikle D., Grimm P., Wyatt R., Arar M., Liereman D., Bridges N., Harmon W., Springate J., Warshaw B., El-Dahr S., Bartosh S., Hurley R., Grimm P., Benfield M., McDonald R., Lum G., Weiss R., Kadry Z., Davis I., Fennel R., Munoz R., Mendley S., Wong C., Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. American Journal of Transplantation 2008 8 5 984 989 2-s2.0-42149091128 10.1111/j.1600-6143.2008. 02167.x (Pubitemid 351537758)
49. Uribe M., Hunter B., Alba A., Calabrán L., Flores L., Soto P., Herzog C., Posttransplant lymphoproliferative disorder in pediatric liver transplantation. Transplantation Proceedings 2009 41 6 2679 2681 2-s2.0-68949205628 10.1016/j.transproceed.2009.06.132
50. Heslop H. E., How I treat EBV lymphoproliferation. Blood 2009 114 19 4002 4008 2-s2.0-77950394280 10.1182/blood-2009-07-143545
51. Parker A., Bowles K., Bradley J. A., Emery V., Featherstone C., Gupte G., Marcus R., Parameshwar J., Ramsay A., Newstead C., Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients-BCSH and BTS Guidelines. British Journal of Haematology 2010 149 5 693 705 2-s2.0-77952630793 10.1111/j.1365-2141.2010.08160.x
52. Younes A., Samad N., Utility of mTOR inhibition in hematologic malignancies. Oncologist 2011 16 6 730 741 2-s2.0-79959610128 10.1634/theoncologist.2010-0318
53. Nepomuceno R. R., Balatoni C. E., Natkunam Y., Snow A. L., Krams S. M., Martinez O. M., Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Research 2003 63 15 4472 4480 2-s2.0-0042090489 (Pubitemid 36951019)
54. Cullis B., D'Souza R., McCullagh P., Harries S., Nicholls A., Lee R., Bingham C., Sirolimus-induced remission of posttransplantation lymphoproliferative disorder. American Journal of Kidney Diseases 2006 47 5 e67 e72 2-s2.0-33646052253 10.1053/j.ajkd.2006.01.029
55. Krams S. M., Martinez O. M., Epstein-Barr virus, rapamycin, and host immune responses. Current Opinion in Organ Transplantation 2008 13 6 563 568 2-s2.0-60849100558 10.1097/MOT.0b013e3283186ba9
56. Evens A. M., David K. A., Helenowski I., Nelson B., Kaufman D., Kircher S. M., Gimelfarb A., Hattersley E., Mauro L. A., Jovanovic B., Chadburn A., Stiff P., Winter J. N., Mehta J., Van Besien K., Gregory S., Gordon L. I., Shammo J. M., Smith S. E., Smith S. M., Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. Journal of Clinical Oncology 2010 28 6 1038 1046 2-s2.0-77949902071 10.1200/JCO.2009.25.4961
57. Choquet S., Leblond V., Herbrecht R., Socié G., Stoppa A., Vandenberghe P., Fischer A., Morschhauser F., Salles G., Feremans W., Vilmer E., Peraldi M., Lang P., Lebranchu Y., Oksenhendler E., Garnier J. L., Lamy T., Jaccard A., Ferrant A., Offner F., Hermine O., Moreau A., Fafi-Kremer S., Morand P., Chatenoud L., Berriot-Varoqueaux N., Bergougnoux L., Milpied N., Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006 107 8 3053 3057 2-s2.0-33645740570 10.1182/blood-2005-01-0377
58. Choquet S., Oertel S., LeBlond V., Riess H., Varoqueaux N., Dörken B., Trappe R., Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Annals of Hematology 2007 86 8 599 607 2-s2.0-34347395765 10.1007/s00277-007-0298-2 (Pubitemid 47018478)
59. Oertel S. H. K., Verschuuren E., Reinke P., Zeidler K., Papp-Váry M., Babel N., Trappe R. U., Jonas S., Hummel M., Anagnostopoulos I., Dörken B., Riess H. B., Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). American Journal of Transplantation 2005 5 12 2901 2906 2-s2.0-33644827381 10.1111/j.1600-6143.2005. 01098.x (Pubitemid 43923950)
60. Trappe R., Oertel S., Leblond V., Mollee P., Sender M., Reinke P., Neuhaus R., Lehmkuhl H., Horst H. A., Salles G., Morschhauser F., Jaccard A., Lamy T., Leithäuser M., Zimmermann H., Anagnostopoulos I., Raphael M., Riess H., Choquet S., Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. The Lancet Oncology 2012 13 2 196 206 2-s2.0-84856412562 10.1016/S1470-2045(11) 70300-X
61. Milpied N., Vasseur B., Parquet N., Garnier J. L., Antoine C., Quartier P., Carret A. S., Bouscary D., Faye A., Bourbigot B., Reguerre Y., Stoppa A. M., Bourquard P., Hurault De Ligny B., Dubief F., Mathieu-Boue A., Leblond V., Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Annals of Oncology 2000 11 1 S113 S116 2-s2.0-0033997255 (Pubitemid 30111878)
62. Serinet M. O., Jacquemin E., Habes D., Debray D., Fabre M., Bernard O., Anti-CD20 monoclonal antibody (rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients. Journal of Pediatric Gastroenterology and Nutrition 2002 34 4 389 393 2-s2.0-0036260310 10.1097/00005176-200204000-00014 (Pubitemid 34568542)
63. Gross T. G., Orjuela M. A., Perkins S. L., Park J. R., Lynch J. C., Cairo M. S., Smith L. M., Hayashi R. J., Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group Report. American Journal of Transplantation 2012 12 3069 3075
64. Gupta S., Fricker F. J., González-Peralta R. P., Slayton W. B., Schuler P. M., Dharnidharka V. R., Post-transplant lymphoproliferative disorder in children: recent outcomes and response to dual rituximab/low-dose chemotherapy combination. Pediatric Transplantation 2010 14 7 896 902 2-s2.0-78349235420 10.1111/j.1399-3046.2010.01370.x
65. Elstrom R. L., Andreadis C., Aqui N. A., Ahya V. N., Bloom R. D., Brozena S. C., Olthoff K. M., Schuster S. J., Nasta S. D., Stadtmauer E. A., Tsai D. E., Treatment of PTLD with rituximab or chemotherapy. American Journal of Transplantation 2006 6 3 569 576 2-s2.0-33644891006 10.1111/j.1600-6143.2005. 01211.x (Pubitemid 43382145)
66. Jain A. B., Marcos A., Pokharna R., Shapiro R., Fontes P. A., Marsh W., Mohanka R., Fung J. J., Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center. Transplantation 2005 80 12 1692 1698 2-s2.0-30144440127 10.1097/01.tp.0000185570.41571.df (Pubitemid 43053993)
67. Fohrer C., Caillard S., Koumarianou A., Ellero B., Woehl-Jaeglé M., Meyer C., Epailly E., Chenard M., Lioure B., Natarajan-Ame S., Maloisel F., Lutun P., Kessler R., Moulin B., Bergerat J., Wolf P., Herbrecht R., Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen. British Journal of Haematology 2006 134 6 602 612 2-s2.0-33747437291 10.1111/j.1365-2141.2006.06228.x (Pubitemid 44253602)
68. Burkhardt B., Oschlies I., Klapper W., Zimmermann M., Woessmann W., Meinhardt A., Landmann E., Attarbaschi A., Niggli F., Schrappe M., Reiter A., Non-Hodgkin's lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols. Leukemia 2011 25 1 153 160 2-s2.0-78651295815 10.1038/leu.2010.245
69. Schechter-Finkelstein T., Gassas A., Weitzman S., Grant D., Pollock-Barziv S., Dipchand A., Alexander S., Ali M., Avitzur Y., Doyle J., Hematopoietic stem-cell transplantation following solid-organ transplantation in children. Bone Marrow Transplantation 2011 46 10 1321 1325 2-s2.0-80054001151 10.1038/bmt.2011.153
70. Picarsic J., Jaffe R., Mazariegos G., Webber S. A., Ellis D., Green M. D., Reyes-Múgica M., Post-transplant Burkitt lymphoma is a more aggressive and distinct form of post-transplant lymphoproliferative disorder. Cancer 2011 117 19 4540 4550 2-s2.0-80052932942 10.1002/cncr.26001
71. Zimmermann H., Reinke P., Neuhaus R., Lehmkuhl H., Oertel S., Atta J., Planker M., Gärtner B., Lenze D., Anagnostopoulos I., Riess H., Trappe R. U., Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients. Cancer 2012 118 19 4715 4724 2-s2.0-84857671852 10.1002/cncr.27482
72. Tiede C., Maecker-Kolhoff B., Klein C., Kreipe H., Hussein K., Risk factors and prognosis in T-cell posttransplantation lymphoproliferative diseases: reevaluation of 163 cases. Transplantation 2013 95 3 479 488 10.1097/TP.0b013e3182762e07
73. Yang F., Li Y., Braylan R., Hunger S. P., Yang L., Pediatric T-cell post-transplant lymphoproliferative disorder after solid organ transplantation. Pediatric Blood and Cancer 2008 50 2 415 418 2-s2.0-37549036712 10.1002/pbc.21072
74. Morton M., Coupes B., Roberts S. A., Klapper P. E., Byers R. J., Vallely P. J., Ryan K., Picton M. L., Epidemiology of posttransplantation lymphoproliferative disorder in adult renal transplant recipients. Transplantation 2012 95 3 470 478 10.1097/TP.0b013e318276a237
75. Patrick A., Wee A., Hedderman A., Wilson D., Weiss J., Govani M., High-dose intravenous rituximab for multifocal, monomorphic primary central nervous system posttransplant lymphoproliferative disorder. Journal of Neuro-Oncology 2011 103 3 739 743 2-s2.0-79959791883 10.1007/s11060-010-0425-0
76. Czyzewski K., Styczynski J., Krenska A., Debski R., Zajac-Spychala O., Wachowiak J., Wysocki M., Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder. Leukemia & Lymphoma 54 3 503 506 10.3109/10428194.2012.718342
77. Van De Glind G., De Graaf S., Klein C., Cornelissen M., Maecker B., Loeffen J., Intrathecal rituximab treatment for pediatric post-transplant lymphoproliferative disorder of the central nervous system. Pediatric Blood and Cancer 2008 50 4 886 888 2-s2.0-40449100681 10.1002/pbc.21297 (Pubitemid 351354810)
78. Schiff D., Cavaliere R., Reply to primary central nervous system post-transplantation lymphoproliferative disorder. Cancer 2010 116 14 3521 3522 2-s2.0-77954906091 10.1002/cncr.25338
79. Taj M. M., Messahel B., Mycroft J., Pritchard-Jones K., Baker A., Height S., Hadzic N., Pinkerton C. R., Efficacy and tolerability of high-dose methotrexate in central nervous system positive or relapsed lymphoproliferative disease following liver transplant in children. British Journal of Haematology 2008 140 2 191 196 2-s2.0-37249052350 10.1111/j.1365-2141.2007.06896.x (Pubitemid 350265042)
80. Pirsch J. D., Stratta R. J., Sollinger H. W., Hafez G. R., D'Alessandro A. M., Kalayoglu M., Belzer F. O., Treatment of severe Epstein-Barr virus-induced lymphoproliferative syndrome with ganciclovir: two cases after solid organ transplantation. American Journal of Medicine 1989 86 2 241 244 2-s2.0-0024495517 (Pubitemid 19049642)
81. Nozzoli C., Bartolozzi B., Guidi S., Orsi A., Vannucchi A. M., Leoni F., Bosi A., Epstein-Barr virus-associated post-transplant lymphoproliferative disease with central nervous system involvement after unrelated allogeneic hematopoietic stem cell transplantation. Leukemia and Lymphoma 2006 47 1 167 169 2-s2.0-30844439440 10.1080/10428190500254208 (Pubitemid 43101743)
82. Meng Q., Hagemeier S. R., Fingeroth J. D., Gershburg E., Pagano J. S., Kenney S. C., The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production. Journal of Virology 2010 84 9 4534 4542 2-s2.0-77950850768 10.1128/JVI.02487-09
83. Perrine S. P., Hermine O., Small T., Suarez F., O'Reilly R., Boulad F., Fingeroth J., Askin M., Levy A., Mentzer S. J., Di Nicola M., Gianni A. M., Klein C., Horwitz S., Faller D. V., A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 2007 109 6 2571 2578 2-s2.0-33947275876 10.1182/blood-2006- 01-024703 (Pubitemid 46425904)
84. Oertel S. H. K., Ruhnke M. S., Anagnostopoulos I., Kahl A. A. A. H., Frewer A. F. W., Bechstein W. O., Hummel M. W., Riess H. B., Treatment of Epstein-Barr virus-induced posttransplantation lymphoproliferative disorder with Foscarnet alone in an adult after simultaneous heart and renal transplantation. Transplantation 1999 67 5 765 767 2-s2.0-0033559062 (Pubitemid 29161723)
85. Comoli P., Maccario R., Locatelli F., Valente U., Basso S., Garaventa A., Tomà P., Botti G., Melioli G., Baldanti F., Nocera A., Perfumo F., Ginevri F., Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells. American Journal of Transplantation 2005 5 6 1415 1422 2-s2.0-20544449381 10.1111/j.1600-6143. 2005.00854.x (Pubitemid 40839433)
86. Khanna R., Bell S., Sherritt M., Galbraith A., Burrows S. R., Rafter L., Clarke B., Slaughter R., Falk M. C., Douglass J., Williams T., Elliott S. L., Moss D. J., Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proceedings of the National Academy of Sciences of the United States of America 1999 96 18 10391 10396 2-s2.0-13044295992 10.1073/pnas.96.18.10391 (Pubitemid 29422568)
87. Savoldo B., Goss J. A., Hammer M. M., Zhang L., Lopez T., Gee A. P., Lin Y., Quiros-Tejeira R. E., Reinke P., Schubert S., Gottschalk S., Finegold M. J., Brenner M. K., Rooney C. M., Heslop H. E., Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 2006 108 9 2942 2949 2-s2.0-33750836784 10.1182/blood-2006-05- 021782
88. Sherritt M. A., Bharadwaj M., Burrows J. M., Morrison L. E., Elliott S. L., Davis J. E., Kear L. M., Slaughter R. E., Bell S. C., Galbraith A. J., Khanna R., Moss D. J., Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy. Transplantation 2003 75 9 1556 1560 2-s2.0-0037910274 10.1097/01.TP.0000058745.02123.6F (Pubitemid 36597295)
89. Haque T., Wilkie G. M., Jones M. M., Higgins C. D., Urquhart G., Wingate P., Burns D., McAulay K., Turner M., Bellamy C., Amlot P. L., Kelly D., MacGilchrist A., Gandhi M. K., Swerdlow A. J., Crawford D. H., Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007 110 4 1123 1131 2-s2.0-34548025068 10.1182/blood-2006-12-063008 (Pubitemid 47281407)
90. Haque T., Wilkie G. M., Taylor C., Amlot P. L., Murad P., Iley A., Dombagoda D., Britton K. M., Swerdlow A. J., Crawford D. H., Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. The Lancet 2002 360 9331 436 442 2-s2.0-0037055714 10.1016/S0140-6736(02)09672-1 (Pubitemid 34880139)
91. Rooney C. M., Smith C. A., Ng C. Y. C., Loftin S. K., Sixbey J. W., Gan Y., Srivastava D., Bowman L. C., Krance R. A., Brenner M. K., Heslop H. E., Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998 92 5 1549 1555 2-s2.0-0032170108 (Pubitemid 28406858)
92. Wilkie G. M., Taylor C., Jones M. M., Burns D. M., Turner M., Kilpatrick D., Amlot P. L., Crawford D. H., Haque T., Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of Epstein-Barr virus-associated diseases. Journal of Immunotherapy 2004 27 4 309 316 2-s2.0-3042600551 (Pubitemid 38833327)
93. Uhlin M., Gertow J., Uzunel M., Okas M., Berglund S., Watz E., Brune M., Ljungman P., Maeurer M., Mattsson J., Rapid salvage treatment with virus-specific T cells for therapy-resistant disease. Clinical Infectious Diseases 2012 55 1064 1073
94. Moosmann A., Bigalke I., Tischer J., Schirrmann L., Kasten J., Tippmer S., Leeping M., Prevalšek D., Jaeger G., Ledderose G., Mautner J., Hammerschmidt W., Schendel D. J., Kolb H., Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood 2010 115 14 2960 2970 2-s2.0-77951058615 10.1182/blood-2009-08-236356
95. Icheva V., Kayser S., Wolff D., Tuve S., Kyzirakos C., Bethge W., Greil J., Albert M. H., Schwinger W., Nathrath M., Schumm M., Stevanovic S., Handgretinger R., Lang P., Feuchtinger T., Adoptive transfer of Epstein-Barr Virus (EBV) nuclear antigen 1-specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic atem-cell transplantation. Journal of Clinical Oncology 2013 31 39 48
96. Pagliara D., Savoldo B., Cytotoxic T lymphocytes for the treatment of viral infections and posttransplant lymphoproliferative disorders in transplant recipients. Current Opinion in Infectious Diseases 2012 25 431 437
97. + T cells by using virus-like particles. Journal of Virology 2008 82 8 3903 3911 2-s2.0-41949140644 10.1128/JVI.02227-07 (Pubitemid 351521227)
98. + T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response. The Journal of Experimental Medicine 2013 210 5 933 949 10.1084/jem.20121437
99. Bollard C. M., Rooney C. M., Heslop H. E., T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nature Reviews Clinical Oncology 2012 9 510 519
100. Gross T. G., Bucuvalas J. C., Park J. R., Greiner T. C., Hinrich S. H., Kaufman S. S., Langnas A. N., McDonald R. A., Ryckman F. C., Shaw B. W., Sudan D. L., Lynch J. C., Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. Journal of Clinical Oncology 2005 23 27 6481 6488 2-s2.0-27244449778 10.1200/JCO.2005.08.074 (Pubitemid 46190239)
101. Dharnidharka V. R., Martz K. L., Stablein D. M., Benfield M. R., Improved survival with recent post-transplant lymphoproliferative disorder (PTLD) in children with kidney transplants. American Journal of Transplantation 2011 11 4 751 758 2-s2.0-79953254320 10.1111/j.1600-6143.2011.03470.x
102. Orjuela M. A., Alobeid B., Liu X., Siebert A. L., Kott E. R., Addonizio L. J., Morris E., Garvin J. H., Lobritto S. J., Cairo M. S., CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation. British Journal of Haematology 2011 152 6 733 742 2-s2.0-79951995836 10.1111/j.1365-2141.2010.08448.x
103. Bingler M. A., Feingold B., Miller S. A., Quivers E., Michaels M. G., Green M., Wadowsky R. M., Rowe D. T., Webber S. A., Chronic high Epstein-Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease/lymphoma in children. American Journal of Transplantation 2008 8 2 442 445 2-s2.0-38149027702 10.1111/j.1600-6143.2007.02080.x
104. Schubert S., Renner C., Hammer M., Abdul-Khaliq H., Lehmkuhl H. B., Berger F., Hetzer R., Reinke P., Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients. Journal of Heart and Lung Transplantation 2008 27 1 100 105 2-s2.0-37749022131 10.1016/j.healun.2007.09.027
105. Green M., Soltys K., Rowe D. T., Webber S. A., Mazareigos G., Chronic high Epstein-Barr viral load carriage in pediatric liver transplant recipients. Pediatric Transplantation 2009 13 3 319 323 2-s2.0-64149112298 10.1111/j.1399-3046.2008.00926.x
106. Lau A. H., Soltys K., Sindhi R. K., Bond G., Mazariegos G. V., Green M., Chronic high Epstein-Barr viral load carriage in pediatric small bowel transplant recipients. Pediatric Transplantation 2010 14 4 549 553 2-s2.0-77952274815 10.1111/j.1399-3046.2009.01283.x
107. Stevens S. J. C., Verschuuren E. A. M., Pronk I., Van Der Bij W., Harmsen M. C., The T. H., Meijer C. J. L. M., Van Den Brule A. J. C., Middeldorp J. M., Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001 97 5 1165 1171 2-s2.0-0035283115 10.1182/blood.V97.5.1165 (Pubitemid 32183736)
108. Ruf S., Wagner H. J., Determining EBV load: current best practice and future requirements. Expert Review of Clinical Immunology 2013 9 139 151
109. Smets F., Latinne D., Bazin H., Reding R., Otte J., Buts J., Sokal E. M., Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 2002 73 10 1603 1610 2-s2.0-0037182156 (Pubitemid 34568673)
110. Wilsdorf N., Eiz-Vesper B., Henke-Gendo C., Diestelhorst J., Oschlies I., Hussein K., Pape L., Baumann U., Tonshoff B., Pohl M., Hocker B., Wingen A. M., Klapper W., Kreipe H., Schulz T. F., Klein C., Maecker-Kolhoff B., EBV-specific T-cell immunity in pediatric solid organ graft recipients with posttransplantation lymphoproliferative disease. Transplantation 2013 95 247 255
111. Sebelin-Wulf K., Nguyen T. D., Oertel S., Papp-Vary M., Trappe R. U., Schulzki A., Pezzutto A., Riess H., Subklewe M., Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD. Transplant Immunology 2007 17 3 203 210 2-s2.0-33847199387 10.1016/j.trim.2006.10.006
112. Haque T., Chaggar T., Schafers J., Atkinson C., McAulay K. A., Crawford D. H., Soluble CD30: a serum marker for Epstein-Barr virus-associated lymphoproliferative diseases. Journal of Medical Virology 2011 83 2 311 316 2-s2.0-78650376729 10.1002/jmv.21953
113. Engels E. A., Savoldo B., Pfeiffer R. M., Costello R., Zingone A., Heslop H. E., Landgren O., Plasma markers of B-cell activation and clonality in pediatric liver and hematopoietic stem cell transplant recipients. Transplantation 2013 95 519 526
114. Hinrichs C., Wendland S., Zimmermann H., Eurich D., Neuhaus R., Schlattmann P., Babel N., Riess H., Gärtner B., Anagnostopoulos I., Reinke P., Trappe R. U., IL-6 and IL-10 in post-transplant lymphoproliferative disorders development and maintenance: a longitudinal study of cytokine plasma levels and T-cell subsets in 38 patients undergoing treatment. Transplant International 2011 24 9 892 903 2-s2.0-80051695525 10.1111/j.1432-2277.2011. 01282.x
115. Schiffer L., Gendo C. H., Wilsdorf N., Hussein K., Pape L., Schmitt C., Haller H., Schiffer M., Klein C., Kreipe H., Kolhoff B. M., CXCL13 as a novel marker for diagnosis and disease monitoring in pediatric PTLD. American Journal of Transplantation 2012 12 1610 1617 2-s2.0-84857020504 10.1111/j.1600-6143. 2011.03968.x
116. von Falck C., Maecker B., Schirg E., Boerner A. R., Knapp W. H., Klein C., Galanski M., Post transplant lymphoproliferative disease in pediatric solid organ transplant patients: a possible role for [18F]-FDG-PET(/CT) in initial staging and therapy monitoring. European Journal of Radiology 2007 63 3 427 435 2-s2.0-34548272711 10.1016/j.ejrad.2007.01.007 (Pubitemid 47321032)
117. Oertel S., Trappe R. U., Zeidler K., Babel N., Reinke P., Hummel M., Jonas S., Papp-Vary M., Subklewe M., Dörken B., Riess H., Gärtner B., Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course. Annals of Hematology 2006 85 7 478 484 2-s2.0-33747833754 10.1007/s00277-006-0109-1 (Pubitemid 44283116)
118. Opelz G., Daniel V., Naujokat C., Fickenscher H., Döhler B., Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis. Lancet Oncology 2007 8 3 212 218 2-s2.0-33847136032 10.1016/S1470-2045(07)70040- 2 (Pubitemid 46291703)
119. Comoli P., Basso S., Zecca M., Pagliara D., Baldanti F., Bernardo M. E., Barberi W., Moretta A., Labirio M., Paulli M., Furione M., Maccario R., Locatelli F., Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. American Journal of Transplantation 2007 7 6 1648 1655 2-s2.0-34248659404 10.1111/j.1600-6143.2007. 01823.x (Pubitemid 46776261)
120. Merlo A., Turrini R., Dolcetti R., Martorelli D., Muraro E., Comoli P., Rosato A., The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders. Haematologica 2010 95 10 1769 1777 2-s2.0-77957305114 10.3324/haematol.2010.023689
121. Sokal E. M., Hoppenbrouwers K., Vandermeulen C., Moutschen M., Léonard P., Moreels A., Haumont M., Bollen A., Smets F., Denis M., Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. Journal of Infectious Diseases 2007 196 12 1749 1753 2-s2.0-39149121505 10.1086/523813 (Pubitemid 351411934)
122. Rees L., Tizard E. J., Morgan A. J., Cubitt W. D., Finerty S., Oyewole-Eletu T. A., Owen K., Royed C., Stevens S. J., Shroff R. C., Tanday M. K., Wilson A. D., Middeldorp J. M., Amlot P. L., Steven N. M., A phase i trial of epstein-barr virus Gp350 vaccine for children with chronic kidney disease awaiting transplantation. Transplantation 2009 88 8 1025 1029 2-s2.0-70350437381 10.1097/TP.0b013e3181b9d918
123. Cohen J. I., Fauci A. S., Varmus H., Nabel G. J., Epstein-Barr virus: an important vaccine target for cancer prevention. Science Translational Medicine 2011 3 107 2-s2.0-80455164859 10.1126/scitranslmed.3002878 107fs7
124. Penn I., Hammond W., Brettschneider L., Starzl T. E., Malignant lymphomas in transplantation patients. Transplantation Proceedings 1969 1 1 106 112 2-s2.0-0014476231
125. Caillard S., Porcher R., Provot F., Dantal J., Choquet S., Durrbach A., Morelon E., Moal V., Janbon B., Alamartine E., Pouteil Noble C., Morel D., Kamar N., Buchler M., Mamzer M. F., Peraldi M. N., Hiesse C., Renoult E., Toupance O., Rerolle J. P., Delmas S., Lang P., Lebranchu Y., Heng A. E., Rebibou J. M., Mousson C., Glotz D., Rivalan J., Thierry A., Etienne I., Moal M. C., Albano L., Subra J. F., Ouali N., Westeel P. F., Delahousse M., Genin R., Hurault de Ligny B., Moulin B., Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score. Journal of Clinical Oncology 2013 31 1302 1309
126. Gustafsson Å., Levitsky V., Zou J., Frisan T., Dalianis T., Ljungman P., Ringden O., Winiarski J., Ernberg I., Masucci M. G., Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000 95 3 807 814 2-s2.0-12944328008 (Pubitemid 30062700)
127. Sun Q., Burton R., Reddy V., Lucas K. G., Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma. British Journal of Haematology 2002 118 3 799 808 2-s2.0-0036037324 10.1046/j.1365-2141.2002.03683.x (Pubitemid 35007385)
128. Gandhi M. K., Wilkie G. M., Dua U., Mollee P. N., Grimmett K., Williams T., Whitaker N., Gill D., Crawford D. H., Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders. American Journal of Transplantation 2007 7 5 1293 1299 2-s2.0-34247380398 10.1111/j.1600-6143.2007.01796.x (Pubitemid 46643124)
129. Barker J. N., Doubrovina E., Sauter C., Jaroscak J. J., Perales M. A., Doubrovin M., Prockop S. E., Koehne G., O'Reilly R. J., Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood 2010 116 23 5045 5049 2-s2.0-78049278080 10.1182/blood-2010-04-281873
130. Heslop H. E., Slobod K. S., Pule M. A., Hale G. A., Rousseau A., Smith C. A., Bollard C. M., Liu H., Wu M., Rochester R. J., Amrolia P. J., Hurwitz J. L., Brenner M. K., Rooney C. M., Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010 115 5 925 935 2-s2.0-77649221824 10.1182/blood-2009-08-239186
131. + lymphomas after allogeneic hematopoietic cell transplantation. Blood 2012 119 11 2644 2656 2-s2.0-84858683311 10.1182/blood-2011-08-371971
132. Morscio J., Dierickx D., Ferreiro J. F., Herreman A., Van Loo P., Bittoun E., Verhoef G., Matthys P., Cools J., Wlodarska I., De Wolf-Peeters C., Sagaert X., Tousseyn T., Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant lymphoproliferative disorders. American Journal of Transplantation 2013 13 5 1305 1316 10.1111/ajt.12196